<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937361</url>
  </required_header>
  <id_info>
    <org_study_id>DZIF TTU 08.824</org_study_id>
    <nct_id>NCT04937361</nct_id>
  </id_info>
  <brief_title>Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network</brief_title>
  <acronym>R-Net</acronym>
  <official_title>Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Survey on the prevalence of MDRO to monitor the import of MDRO from the community. Rectal&#xD;
      swabs will be taken and cultivated. Survey on community-onset and nosocomial bloodstream&#xD;
      infections will be documented and strains will be isolated. For each BSI a clinical data set&#xD;
      will be obtained (e.g. patient age, gender, date of hospitalization, antibiotic therapy).&#xD;
      Genetic analysis of MDRO from the prevalence and BSI study. In a subset of patients the&#xD;
      microbiome-resistome interactome will be analysed in more detail. Furthermore, the impact of&#xD;
      infection control measures due to the Covid-19 pandemic on nosocomial BSI will be&#xD;
      investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>monitoring of MDRO prevalence</measure>
    <time_frame>at hospital admission</time_frame>
    <description>obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>monitoring of blood stream infections</measure>
    <time_frame>during hospitalization, up to 4 weeks</time_frame>
    <description>obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>integrate novel techniques for microbiome-resistome interaction analysis</measure>
    <time_frame>through study completion, after 4 years</time_frame>
    <description>obtain a better understanding for the emergence of resistance within the microenvironment under selective pressure</description>
  </primary_outcome>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>MDRO</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rectal swab</intervention_name>
    <description>collection of rectal swabs</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bacterial strains isolated from rectal swabs, blood cultures and samples derived thereof&#xD;
      (such as purified DNA)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        For the prevalence, adult patients admitted to the hosptial within the last 3 days.&#xD;
&#xD;
        For BSI surveillance, adult inpatients with at least one blood culture positive for any of&#xD;
        the target organisms: Staphylococcus aureus, Enterococcus spp., Escherichia coli,&#xD;
        Enterobacter spp., Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 18 years old&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  inpatient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 18 years old&#xD;
&#xD;
          -  Not capable of giving informed consent&#xD;
&#xD;
          -  outpatient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinik f체r Infektiologie und Mikrobiologie</name>
      <address>
        <city>L체beck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadja K채ding</last_name>
      <phone>+4945131019010</phone>
      <email>nadja.kaeding@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Nadja K채ding</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

